Frontiers in Pharmacology

Efficacy and safety of Nefecon, glucocorticoids, or supportive therapyadded to RASi+SGLT2i in IgA nephropathy

By Tiantian Zhou, Hao Zhang, Shangchao Liu, Yongqiang Ji, Wei Lv

Study in peopleInterventions

The paper

Tiantian Zhou, Hao Zhang, Shangchao Liu, Yongqiang Ji, Wei Lv

Clinical Medical College; Qingdao University

Frontiers in Pharmacology, 26 Aug 2026

doi.org/10.3389/fphar.2026.1897246 PubMed 42688466

Corrected, 6 Oct 2026

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes